About Michael McElhaugh
Michael McElhaugh is a president & CEO, director at Xenagos Bio.
Michael McElhaugh reports to the SEC as a director or officer of 1 public company: Arbutus Biopharma (ABUS).
Michael McElhaugh first appears on SEC filings in 2018.
Experience
This experience comes from Michael McElhaugh's profile and from SEC filings. For roles taken from filings, the years are when the filings name Michael McElhaugh in the role, so the role may have started earlier or lasted longer.
Xenagos Bio, Inc. Current
President & CEO, director
President, Chief Executive Officer and Founder (2025 – Present)
2025 – Present · Philadelphia, PA
Develops targeted cancer therapies for patients with blood and solid tumors.
AC
Arbutus Biopharma Corp
Interim President & CEO, director
Interim President, CEO and Founder (2015 – 2025)
2015 – 2025 · Public company (ABUS)
OI
OnCore Biopharma, Inc.
Chief Operating Officer and Founder
2014 – 2015
BS
Bristol Myers Squibb
Director, Hepatitis C Worldwide Commercialization
2012 – 2014
PI
Pharmasset, Inc.
Director, Business Development and Marketing
2008 – 2012
EP
Ex- Viropharma linkedin page
Manager, Commercial Analysis and Decision Support
2006 – 2008
ME
Merck
Staff Biologist, Department of Viral Vaccine Research
2001 – 2004
Key Colleagues at Startups
The people Michael McElhaugh works with at each company, as listed on that company's latest Form D.
Xenagos Bio, Inc. · Form D, May 15, 2026
AR
Abel De La Rosa
Director
PH
Patrick Higgins
Director